What is the recommended duration of dual antiplatelet therapy after an acute ischemic stroke or high‑risk transient ischemic attack?

Duration of Dual Antiplatelet Therapy After Minor Ischemic Stroke or High-Risk TIA

For patients with minor noncardioembolic ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), initiate dual antiplatelet therapy with aspirin plus clopidogrel within 12-24 hours of symptom onset and continue for 21 days, followed by single antiplatelet therapy. 1

Evidence-Based Duration Recommendation

The 2021 AHA/ASA guideline provides clear direction: DAPT should be continued for 21 to 90 days 1. However, the most recent high-quality evidence strongly favors the shorter end of this range:

• 21-day aspirin-clopidogrel DAPT demonstrates the best risk-benefit profile among all DAPT strategies, with superior net clinical benefit compared to 30-day or 90-day regimens 2, 3
• The ischemic benefit of DAPT is concentrated in the first week, with the benefit-to-risk ratio of 12.87 in week 1, dropping sharply to 1.68 in weeks 2-3 4
• By week 5, DAPT may actually increase ischemic events compared to aspirin alone (RR 3.64) 4

Critical Timing Considerations

Initiate DAPT within 24 hours of symptom onset—this timing is non-negotiable:

• DAPT initiated within 24 hours reduces the composite outcome (recurrent stroke/MI/death) by 26% (HR 0.74) 5
• Between 24-72 hours: no significant benefit (HR 1.00) 5
• Beyond 72 hours: potential harm (HR 1.25) 5
• The therapeutic benefit crosses the null at approximately 42 hours 5

Specific Drug Regimen Selection

Aspirin plus clopidogrel for 21 days is the preferred regimen for most patients:

• Only DAPT strategy not associated with significantly increased major bleeding (OR 1.05) 3
• Reduces recurrent stroke by 32% compared to aspirin alone (OR 0.68) 3
• Superior risk-benefit profile compared to ticagrelor-based regimens 2, 3

Aspirin plus ticagrelor for 21 days may be considered in highly selected cases:

• Provides maximal ischemic protection (OR 0.55 for recurrent stroke) 3
• However, carries 80% increased major bleeding risk (OR 1.80) 3
• Reserve for patients at very high ischemic risk with low bleeding risk

Critical Pitfalls to Avoid

Do not continue DAPT beyond 21-30 days in routine practice:

• The guideline explicitly warns that DAPT beyond 90 days is associated with excess hemorrhage 1
• Recent evidence shows the ischemic benefit attenuates rapidly after week 1, while bleeding risk persists 4
• 90-day DAPT doubles major bleeding risk (OR 2.02) without proportional ischemic benefit 2

Do not delay initiation beyond 24 hours:

• The 24-hour window is when maximum benefit occurs 1, 5
• Ideally initiate within 12 hours if possible 1
• After 42 hours, efficacy becomes questionable 5

Algorithmic Approach

1. Confirm eligibility: Minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), noncardioembolic, presenting within 24 hours
2. Exclude contraindications: No severe carotid stenosis requiring revascularization, no atrial fibrillation requiring anticoagulation, no high bleeding risk
3. Initiate: Aspirin plus clopidogrel within 12-24 hours
4. Duration: Continue for exactly 21 days
5. Transition: Switch to single antiplatelet therapy (aspirin, clopidogrel, or aspirin-dipyridamole) at day 22

Nuances in the Evidence

While the guideline allows up to 90 days of DAPT 1, this recommendation predates the most recent network meta-analyses demonstrating that 21-day regimens provide optimal benefit-risk balance 2, 3. The temporal analysis showing benefit concentration in week 1 with subsequent attenuation 4 provides mechanistic support for shorter durations. The 30-day ticagrelor regimen mentioned in the guideline 1 carries the highest bleeding hazard (OR 2.10) 3 and should be avoided unless specific contraindications to clopidogrel exist.